News & Events

Clean Cells and its partners – OSE Immunotherapeutics SA, INSERM UMR1232/CNRSERL6001, the MicroPiCell platform[1]– have been granted with a €2,4M funding from the Fonds Unique Interministériel (FUI – cofunding from BpiFrance & the Pays de la Loire region) for a 36-month innovative project: “HybridADCC”.

This collaborative project, supported by Atlanpole Biotherapies biocluster, aims at developing a standardised ADCC (Antibody Dependent Cell-mediated Cytotoxicity) assay for testing mouse monoclonal antibodies in a human in vitro context, through the use of a hybrid human/mouse technology. The goal is to identify new antibodies and new therapeutic targets in the huge mouse antibody reservoir before moving these hints forward the human therapeutic field.

Capitalising on the success of Premium ADCC (development of a standardised tool to measure the ADCC activity of human antibodies), Clean Cells will provide its skills in cell culture and in the development of regulatory-compliant potency assays to:

• Optimise manufacturing processes of the new hybrid effector cells while ensuring inter-lot homogeneity
• Develop and evaluate innovative methods to measure the ADCC activity, potentially better suited for murine antibodies’ specific mechanisms

At the end of the 3-year research period, Clean Cells will be able to increase its portfolio of services for the characterisation of therapeutic antibodies and to offer manufacturing & commercialisation services of the hybrid human/mouse effector cells. Our customers will benefit from original tools for early assessment of mouse antibodies to discover new therapeutic targets and/or innovative modes of action.

For more information:

OSE Immunotherapeutics
INSERM UMR1232/CNRSERL6001
The MicroPiCell platform

[1] Part of the Structure Fédérative…